The European Medicines Agency (EMA) has approved an update to the product information for Wegovy injection that allows the medicine to stay at a controlled temperature of up… read more.
Amgen announced positive topline results from a Phase III trial of Tepezza (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid… read more.
Lundbeck announced that new data across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18–22 in Chicago,… read more.
BD (Becton, Dickinson and Company) announced application of CE Mark for the Liverty TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to… read more.
Shionogi & Co., Ltd. announced that they have completed the transfer of all rights for Radicava (edaravone), including intellectual property rights and sales rights, in major countries and… read more.
The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical… read more.
Eli Lilly and Company announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the FDA approval on April 1,… read more.
The European Medicines Agency’s key human medicines committee (CHMP) has recommended five medicines for approval at its March 2026 meeting. This brings to 23 the total number of… read more.
Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for… read more.
Johnson & Johnson announced that the FDA has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients… read more.
Corcept Therapeutics presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Kyinsu (insulin icodec + semaglutide, IcoSema) intended… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
